- Details
- At the 2024 LUGPA annual meeting, Scott Eggener reviews cutting-edge prostate cancer technologies, from screening and imaging to genomic testing and emerging treatments. He provides balanced perspectives on new innovations, emphasizing evidence-based adoption and cautioning against unproven expensive technologies. Biographies: Scott Eggener, Professor of Surgery (Urologic Oncology) and Radiology,...
|
- Details
- Oliver Sartor speaks with Russ Pachynski, Chris Maher, and Aadel Chaudhuri about their novel biomarker study in advanced prostate cancer. The discussion centers on their development of a cell-free DNA assay that examines both AR gene and enhancer alterations in mCRPC patients, showing significant prognostic value for treatment outcomes. Dr. Chaudhuri presents their discovery of a stemness signatur...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Bertrand Tombal challenges traditional salvage radiation approaches in high-risk EMBARK patients. Based on trial results showing enzalutamide's survival benefits, he advocates shifting from radiation-first to systemic ARTA treatment, with radiation as a secondary consideration. Biographies: Bertrand Tombal, MD, PhD, Chairman of the...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Daniel Spratt examines systemic therapy in post-operative biochemical recurrence, challenging universal hormone therapy with salvage radiation. He demonstrates varying benefits based on PSA levels and emphasizes treatment personalization using genomic classifiers and MMAI models. Biographies: Daniel Spratt, MD, Chair and Professor...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Derya Tilki leads a panel with Drs Tombal, Spratt, and Alicja Jereczek-Fossa examining salvage radiation timing, EMBARK trial interpretation, and treatment decision factors in biochemically recurrent prostate cancer, balancing PSA levels and patient-specific characteristics. Biographies: Derya Tilki, MD, Associate Professor of Urol...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Paul Nguyen analyzes treatment approaches for post-prostatectomy and salvage radiation biochemical recurrence, comparing SBRT versus whole pelvis radiation for lymph node metastases. He examines current evidence and ongoing trials informing treatment decisions. Biographies: Paul L. Nguyen, MD, MBA, FASTRO, Baldwin-Politi Distinguis...
|
- Details
- Andrea Miyahara speaks with Sheng-Yu Ku about a Journal of Clinical Investigation publication examining the role of Notch signaling in neuroendocrine prostate cancer. The research demonstrates that Notch signaling acts as a tumor suppressor in neuroendocrine prostate cancer by suppressing neuroendocrine differentiation and inducing prostate luminal lineage development. Dr. Ku's work reveals how No...
|
- Details
- Oliver Sartor speaks with Louise Emmett about combination therapy approaches with lutetium-PSMA in prostate cancer. The discussion explores various combination strategies, including promising results from the ENZA-p trial combining lutetium-PSMA with enzalutamide, which shows notable response rates in first-line mCRPC. They examine multiple potential combination approaches, including hormonal ther...
|
- Details
- Andrea Miyahira speaks with Ayesha Shafi about a study on AR coactivators CBP/p300 in prostate cancer. The research reveals that CBP/p300 expression increases as prostate cancer progresses to castration-resistant stages, correlating with poor patient survival. Through various preclinical studies, Dr. Shafi demonstrates that CBP/p300 plays a crucial role in DNA repair, particularly in homologous re...
|
- Details
- Raunak Shrestha discusses a published study on chromatin accessibility in advanced prostate cancer. The research, which represents the largest collection of ATAC-seq profiles in metastatic prostate cancer to date, reveals distinct chromatin accessibility patterns across different cancer subtypes. The study identifies 203 transcription factors associated with various metastatic prostate cancer subt...
|
